Celltrion Group Chairman Seo Jung-jin will visit key overseas operations in Europe, the United States, Canada, and Japan throughout August to enhance sales in the second half of the year.
According to Celltrion Group, Seo will depart for Paris, France, on August 10, where he will sequentially visit various locations across Europe to directly assess regional sales strategies and supply plans, including the expansion of pharmacy direct sales networks. He will then check on the overall sales and revenue plans at major overseas subsidiaries in the U.S., Canada, and Japan.
This itinerary is not merely a tour of overseas subsidiaries; it focuses on evaluating the global sales execution capabilities necessary to sustain growth in the second half of the year. Seo plans to review market conditions by region, sales status by product, bidding and supply schedules, and plans for expanding into new countries, while also providing immediate decision-making support for challenges raised on-site.
In particular, he will closely examine the sales synergies and strategies with strengthened local subsidiaries following the acquisitions of French healthcare company Gifrer and Swiss pharmaceutical distributor iQone. Celltrion is enhancing its supply competitiveness by expanding its direct sales network to pharmacies in addition to its existing hospital and procurement market focus in Europe. The strategy aims to strengthen market responsiveness by targeting both key distribution channels: hospitals and pharmacies.
Seo intends to listen to local concerns directly and resolve them swiftly to solidify the foundation for revenue growth in the second half of the year.
In the first half of this year, Celltrion reported consolidated revenues of 2.5387 trillion won and an operating profit of 773.7 billion won, marking increases of 40.8% and 97.4%, respectively, compared to the same period last year, achieving the highest half-year performance to date. The growth was driven by stable sales of existing products, the rise of high-margin follow-up products, and the advancement of the global direct sales system.
Notably, new high-margin products like Remsima SC (ingredient: infliximab) accounted for about 65% of total revenue, driving the growth. Celltrion plans to continue this growth trend in the second half by reviewing sales strategies for follow-up products by region, expanding market share, and assessing plans for entering new countries.
In the second half, significant bidding volumes from major European countries are expected to be reflected, along with increased demand for pharmaceutical inventory replenishment by year-end. Celltrion aims to finely adjust country-specific sales strategies based on seasonal demand and competitive environments while managing supply and sales execution to carry forward the growth momentum from the first half.
A Celltrion official stated, "Chairman Seo's direct engagement in enhancing second-half sales while traveling through global sites in Europe, the U.S., and Canada is significant. We will encourage local employees amid the heat and swiftly advance country-specific tasks such as expanding pharmacy direct sales networks to maintain robust growth."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.